Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes.

摘要: Type 1 diabetes (T1D) is an autoimmune disease that generally considered to be T cell-driven. Accordingly, most strategies of immunotherapy for T1D prevention and treatment in the clinic have targeted cell compartment. To date, however, has had only limited clinical success. Although certain immunotherapies promoted a protective effect, efficacy often short-term acquired immunity may impacted. This led consideration combining different approaches with goal achieving synergistic therapeutic response. In this review, we will discuss status various tested clinic, as well possible combinatorial restore β tolerance.